Press Releases

JERSEY CITY, N.J., Nov. 12, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the quarter ended September 30, 2019, and provided an update on recent clinical developments. Ibrexafun

CAMBRIDGE, Mass., Nov. 12, 2019 /PRNewswire/ -- Raytheon (NYSE: RTN) is using synthetic biology science to create a new method for detecting buried explosives, using bacteria as sensors. Under a contract from the U.S. Defense Advanced Research Projects Agency, Raytheon and partner Worcester Polytechnic Institute will program two bacterial stra

SAN JOSE, California and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader, DarioHealth Corp. (NASDAQ: DRIO) announced today the launch of a Dario-powered digital diabetes program with

SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- CLR Roasters, a Miami, Florida based company and wholly owned subsidiary of Youngevity International, Inc. (NASDAQ:YGYI), announced today an expansion of their operating partnership with H&H Coffee Group Export as the parties have entered into an exclusive arrangement to cultivate hemp gro

SAN DIEGO and PENNINGTON, N.J., Nov. 12, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced outcomes from a safety and biomarker analysis on its lead product candidate, TAVO™, at the Society for Immunotherapy of C

SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and nine months ended September 3

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure

ATLANTA, Nov. 12, 2019 /PRNewswire/ -- Parallel, formerly Surterra Wellness, a company that is pioneering human well-being through its proprietary cannabinoid brands, science and technology-led innovation, today announced that Kevin Fisher has been named Chief Operating Officer (COO), effective immediately.  As COO, Fisher will ha

ALLSCHWIL, Switzerland, Nov. 12, 2019 /PRNewswire/ -- Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has announced its decision to voluntarily withdraw the European and other health authority filings still under review to extend the indication of OPSUMIT® (macitentan) to include the treatment of adu

SEATTLE, Nov. 12, 2019 /PRNewswire/ -- Faraday Pharmaceuticals, a biopharmaceutical company focused on the development of elemental reducing agents for critical care medicine, today announced that top-line results from its Phase 2 trial of FDY-5301 will be presented at the American Heart Association (AHA) Scientific Sessions 2019 taking place